All News

The new data may put to rest concerns that adding perioperative systemic therapy might worsen outcomes in patients slated for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.

Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.

The anti–PD-1 antibody is being assessed as therapy for patients with recurrent or metastatic cervical cancer after positive results indicate improved responses with the monotherapy.

Radioligand therapy 177Lu-PSMA-617 receives breakthrough designation from the FDA based on better overall survival outcomes in patients with metastatic castration-resistant prostate cancer.

Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status.

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Patients who had resection within 12 weeks of diagnosis of stage I NSCLC were found to have lower rates of recurrence.

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.

Agha detailed updated findings from CARTITUDE-2 investigating cilta-cel for previously treated patients with multiple myeloma.

CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta) showed promise in patients with high-risk relapsed/refractory indolent non-Hodgkin lymphoma.

Bemcentinib plus PD-1/L1 inhibition moves forward as therapy for patients with AXL-expressing non–small cell lung cancer.

Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

Look at some of the important updates from last week you might have missed from the 2021 ASCO Annual Meeting and the FDA.

Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Retrospective data presented at 2021 EHA revealed potential treatment gaps in the management of patients with myeloproliferative neoplasms.

A progression-free survival advantage persisted at the 3-year mark with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Treatment with axicabtagene ciloleucel resulted in improved survival and tumor responses in patients with relapsed/refractory follicular lymphoma versus other available therapies.

Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.

The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma.

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Patients with myeloma who received bortezomib, thalidomide, and dexamethasone with autologous stem cell transplant had better response duration when daratumumab was used as maintenance therapy.

Among other things, Pennell focused on data regarding atezolizumab as adjuvant therapy to improve disease-free survival for patients with stage II/III resected non–small cell lung cancer.

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.